This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CDAK Codiak BioSciences (CDAK) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Codiak BioSciences Stock (NASDAQ:CDAK) 30 days 90 days 365 days Advanced Chart Get Codiak BioSciences alerts:Sign Up Key Stats Today's Range$0.0016▼$0.001650-Day Range N/A52-Week Range$0.05▼$6.98VolumeN/AAverage Volume1.37 million shsMarket Capitalization$58,928.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCodiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More… Receive CDAK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Codiak BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CDAK Stock News HeadlinesMarvel Biosciences Corp MRVLJanuary 13, 2024 | morningstar.comMariana Oncology Expands Management Team, Appoints Linda Bain Chief Operating Officer and Chief Financial OfficerMay 19, 2023 | finance.yahoo.comIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to protect your 401(k), IRA, or pension from market chaos and currency collapse? The 2025 Wealth Protection Guide reveals a legal IRS strategy that may let you keep more of your retirement—regardless of what happens next. Trump’s warning was real. So is this opportunity.May 29, 2025 | Colonial Metals (Ad)CDAK.OApril 15, 2023 | reuters.comHow Does Codiak BioSciences Inc (CDAK) Stock Rank on Wall Street Friday?April 2, 2023 | benzinga.comCodiak BioSciences Files For Chapter 11 BankruptcyMarch 27, 2023 | finance.yahoo.comCodiak BioSciences Shares Hit 52-Week Low After Bankruptcy FilingMarch 27, 2023 | marketwatch.comStruggling MD Anderson spinout files for bankruptcy protectionMarch 27, 2023 | bizjournals.comSee More Headlines CDAK Stock Analysis - Frequently Asked Questions How were Codiak BioSciences' earnings last quarter? Codiak BioSciences, Inc. (NASDAQ:CDAK) released its quarterly earnings results on Thursday, November, 4th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.85) by $0.12. The company earned $1.16 million during the quarter, compared to analyst estimates of $2.87 million. Codiak BioSciences had a negative net margin of 51.13% and a negative trailing twelve-month return on equity of 109.51%. When did Codiak BioSciences IPO? Codiak BioSciences (CDAK) raised $82 million in an initial public offering on Wednesday, October 14th 2020. The company issued 5,500,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Evercore ISI, William Blair and Wedbush PacGrow acted as the underwriters for the IPO. What other stocks do shareholders of Codiak BioSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Codiak BioSciences investors own include NIO (NIO), Advanced Micro Devices (AMD), Alibaba Group (BABA), NVIDIA (NVDA), PayPal (PYPL), Tesla (TSLA) and Plug Power (PLUG). Company Calendar Last Earnings11/04/2021Today5/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CDAK CIK1659352 Webwww.codiakbio.com Phone617-949-4100FaxN/AEmployees102Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$37.16 million Net Margins-51.13% Pretax Margin-51.13% Return on Equity-109.51% Return on Assets-34.44% Debt Debt-to-Equity Ratio0.66 Current Ratio4.24 Quick Ratio4.24 Sales & Book Value Annual Sales$33.57 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$2.39 per share Price / Book0.00Miscellaneous Outstanding Shares36,830,000Free Float33,810,000Market Cap$58,928.00 OptionableNot Optionable Beta3.71 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:CDAK) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Codiak BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Codiak BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.